Adthera Bio breaks from stealth with venture funding and thought leadership team

Today, Adthera bio limited announced coming out of stealth with well-funded backing from Delin Ventures and a hugely experienced leadership team.

  • Focused exclusively on cell and gene therapy advanced therapy medicinal products (ATMP’s)
  • World renowned team with proven track records in ATMP development & manufacturing, innovation and biopharma
  • Cutting-edge purpose-built facilities and equipment
  • Digital mindset to enable new levels of transparent partnership
  • Well-funded venture-backed and currently revenue generating CDMO.

The cell and gene therapy (CGT) world has grown exponentially in recent years and academic and biotech businesses have sought help to turn their ideas into viable therapies. The team at adthera have well over 100 years of combined experience in this space to bring optimised quality and timelines to highly tailored solutions for partner clients. Their multi-site, highly digital and integrated approach brings together the best of all technical, scientific and managerial approaches. This enables them to partner in a seamless manner, sharing a passion to bring ATMPs to the right patient, in the right way and at the right time across all target diseases from cancer to inflammation and beyond.

Colin Sims, CEO said: “It is a privilege to be part of such an outstanding team whose mission is to bring more of these amazing ATMP treatments to patients who urgently need them. We have experts at board level helping us shape and define new precedents in go-to-market, development and regulatory frameworks”. The company has offices in London, and Birmingham, UK, including both process development and analytical laboratory facilities and a separate GMP production unit.

Speaking about the new facilities, Stuart Curbishley, Chief Development and Manufacturing Officer said: “We have built state-of-the-art laboratories with all the latest technology enabling us to truly partner and tailor processes to give an exceptional level of support to our projects. We even have the first Miltenyi Biotec Prodigy integrated workstations in the UK and our purpose-built, platform-agnostic suite is cutting edge for our partners to come and see for themselves”.

The team at adthera bio have further built a mock clean suite for both training and process refinement purposes. This allows every process to be trained on, and simulated in absolute detail, before entering a GMP suite for production – maximising success and minimising risks, hurdles and costs incurred by process flaws very early on.

The broader team have great depth in experience gained from public institutions like the SNBTS (Scottish National Blood Transfusion Service) and academic centres of excellence alongside existing blue-chip names like GSK, Novartis, Sanofi, Miltenyi Biotec and managerial planning support like BCG and Accenture.

Talking to the depth of scientific and technical experience John Campbell, Chief Scientific Officer said: “We really have a hand-picked team of the best talent in the field, in wonderful new facilities with the latest equipment, training and thinking. Partnering with us will be a transparent and exciting journey relentlessly focused on delivering high-quality products for patients. Our deep understanding of technology to produce ATMPs will benefit all our partners, regardless of disease target or therapeutic approach”

The Board of Directors includes leading industry experts like Hilary Malone the former Chief Regulatory Officer at Sanofi and biotech c-suite, and Carol Lynch, former Chief Business Officer at Sandoz and Delin Ventures Board Member.


More within